BETTER
UNDERSTANDING,
BETTER DECISIONS

INNOVATION NOT ONLY INCLUDES THE DESIGN OF NEW THERAPEUTIC STRATEGIES BUT ALSO THE MANNER IN WHICH CLINICAL TRIALS ARE IMPLEMENTED.

WE

TALK ABOUT

LIVES

THE MEDSIR CONCEPT OF PROVIDING A PLATFORM TO FACILITATE THE DEVELOPMENT OF IDEAS INTO STRATEGIC CLINICAL STUDY PROTOCOLS IS BECOMING MORE DIVERSE, INCORPORATING NOT ONLY NEW TUMOR TYPES, BUT ALSO MODERN AND INNOVATIVE TRIAL DESIGNS SUCH AS UMBRELLA AND MULTI-TUMOR BASKET TRIALS.

WORKING ON A NEW CLINICAL PROJECT WITH THE EXPECTATION THAT IT WILL HELP MANY PATIENTS IS EXHILARATING FOR
MEDSIR, A JOB WELL DONE MEANS RESULTS THAT HAVE THE POTENTIAL TO CHANGE CLINICAL PRACTICE.

HERE YOU WILL FIND OUR COMPREHENSIVE PROJECT PORTFOLIO. 
PLEASE CONTACT US FOR FURTHER INFORMATION.


“LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS”

 

AZENT

(LUNG CANCER)

EXCAAPE

(GENITOURINARY TUMORS)

ZZFIRST

(GENITOURINARY TUMORS)

ORPHEUS

(GENITOURINARY TUMORS)

COPERNICO

(INFECTIOUS DISEASES)

OUR PROJECTS

OPEN PROJECTS
 

BIOPER

(BREAST CANCER)

KELLY

(BREAST CANCER)

TRANSFAL

(BREAST CANCER)

PHERGAIN

(BREAST CANCER)

THELMA

(BREAST CANCER)

BARBICAN

(BREAST CANCER)

LINGAIN

(BREAST CANCER)

OPHELIA

(BREAST CANCER)

PIQUR

(BREAST CANCER)

LUZERN

(BREAST CANCER)

CALADRIO

(BREAST CANCER)

NOBROLA

(BREAST CANCER)

PALMIRA

(BREAST CANCER)

POLEN

(GENITOURINARY TUMORS)

RESPONSE

(BREAST CANCER)

DXCARTES

(BREAST CANCER)

PARSIFAL

(BREAST CANCER)

PHENOMENAL

(BREAST CANCER)

REVERT

(BREAST CANCER)

AZENT

(LUNG CANCER)

SLLIP

(LUNG CANCER)

EXCAAPE

(GENITOURINARY TUMOURS)

EXCAAPE

(GENITOURINARY TUMOURS)

EXCAAPE

(GENITOURINARY TUMOURS)

EXCAAPE

(GENITOURINARY TUMOURS)

EXCAAPE

(GENITOURINARY TUMOURS)

LUPER

(LUNG CANCER)

U.S. National Libary of Medicine

PUBLICATIONS

THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS OR ORAL PRESENTATIONS.

YEAR

CONGRESS

ABSTRACT (Posters, presentations, etc.)

PROJECT

KELLY

A phase II study of pembrolizumab and eribulin in patients with HRpositive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes.

download.png

SABCS

2019

REVERT

A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy (REVERT).

download.png

SABCS

2019

TRANSFAL

Prospective evaluation of predictive/prognostic biomarkers for palbociclib and endocrine therapy in ER positive HER2 negative advanced metastatic breast cancer within the PARSIFAL clinical trial.

download.png

SABCS

2019

PALMIRA

PALbociclib rechallenge in horMone receptor-posItive/HER2-negative Advanced breast cancer.

download.png

ESMO

2019

OPHELIA

Effectiveness of olaparib plus trastuzumab in HER2-positive BRCA-mutated or Homologous Recombination Deficiency (HRD) advanced breast cancer patients.

download.png

ESMO

2019

Other MedSIR related articles

LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.